SIREN : 401258801
THETAPHARM is a French company founded 30 years ago, specialized in the sector Activités des agences de publicité. Based in MONTROUGE (92120), this company of category PME shows in 2023 a revenue of 3.2 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-02
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 3 191 189 € | 2 602 070 € | N/C | N/C | N/C | N/C | 2 714 889 € | 2 511 683 € |
| Net income | 872 693 € | 468 826 € | 385 855 € | 276 823 € | 206 902 € | 185 981 € | 84 606 € | 111 448 € |
| EBITDA | 531 480 € | 477 639 € | N/C | N/C | N/C | N/C | 238 508 € | 171 291 € |
| Net margin | 27.3% | 18.0% | N/C | N/C | N/C | N/C | 3.1% | 4.4% |
In 2023, THETAPHARM achieves revenue of 3.2 M€. Revenue is growing positively over 8 years (CAGR: +3.5%). Vs 2022, growth of +23% (2.6 M€ -> 3.2 M€). After deducting consumption (529 k€), gross margin stands at 2.7 M€, i.e. a rate of 83%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 531 k€, representing 16.7% of revenue. This high EBITDA margin provides strong self-financing capacity and resilience to uncertainties. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 873 k€, i.e. 27.3% of revenue. This profit can be retained or distributed to shareholders.
3 191 189 €
2 661 830 €
531 480 €
515 074 €
872 693 €
16.7%
The debt ratio (= Financial debt / Equity x 100) stands at 0%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 54%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Cash flow represents 27.8% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. This high level provides strong self-financing capacity.
0.026%
54.465%
27.813%
0.0
23.9%
In 2023, the debt ratio of THETAPHARM (0.03) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.
In 2023, the financial autonomy of THETAPHARM (54.5%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.
In 2023, the repayment capacity of THETAPHARM (0.00) ranks in the bottom 25% of the sector, which is positive. This ratio indicates the number of years needed to repay debt with cash flow. A short capacity reflects controlled debt and good cash generation.
The liquidity ratio (= Current assets / Current liabilities) stands at 244.35. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 0.2x. Danger: operating income does not cover interest charges, unsustainable situation.
244.351
0.199
In 2023, the liquidity ratio of THETAPHARM (244.35) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.
In 2023, the interest coverage of THETAPHARM (0.2x) ranks above the median of the sector. This ratio indicates how many times operating income covers interest expenses. This comfortable position offers an appreciable safety margin.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 66 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 57 days. The company must finance 9 days of gap between collections and payments. Inventory turnover is 8 days (= Average inventory / Cost of goods x 360). Fast turnover, sign of good inventory management. Overall, WCR represents 30 days of revenue, i.e. 266 k€ to permanently finance. Over 2016-2023, WCR increased by +152%, requiring additional financing.
266 400 €
66 j
57 j
8 j
30 j
Based on 68 transactions of similar company sales
(all years),
the value of THETAPHARM is estimated at
1 486 770 €
(range 553 520€ - 5 284 131€).
With an EBITDA of 531 480€, the sector multiple of 2.9x is applied.
The price/revenue ratio is 0.22x
(conservative valuation).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Medium reliability: estimate to be confirmed with in-depth analysis.
Ajustez les pondérations selon votre analyse
This estimate is based on the analysis of 68 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare THETAPHARM with other companies in the same sector:
Voir toutes les statistiques du secteur Activités des agences de publicité
The revenue of THETAPHARM in 2023 is 3.2 M€.
Yes, THETAPHARM generated a net profit of 873 k€ in 2023.
The headquarters of THETAPHARM is located in MONTROUGE (92120), in the department Hauts-de-Seine.
The tax return of THETAPHARM is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
THETAPHARM operates in the sector Activités des agences de publicité (NAF code 73.11Z). See the 'Sector positioning' section above to compare the company with its competitors.